TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03332940

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tc 99M Sulfur Colloid
Description: Sulfur colloid is a radiotracer that is indicated for imaging areas of functional reticuloendothelial cells in the liver, spleen, and bone marrow.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tc99m-tilmanocept
Description: Tilmanocept is a radiotracer that accumulates in macrophages by binding to a mannose binding receptor that resides on the surface.
Study: NCT02047149

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zileuton (Zyflo®) Dasatinib (Sprycel®)
Description: To determine the maximum dose of zileuton/dasatinib in subjects with CML
Study: NCT00006265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ara-C
Description: 3 g/sq m IV infusion over 3 hours Days 1-5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ara-C
Description: 3 g/sq m IV infusion over 3 hours Days 1-5
Study: NCT02047149

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dosing with Zileuton/Dasatinib in CML
Description: Three dose levels of daily zileuton will be studied in conjunction with dasatinib to define the MTD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daily dosing of Zileuton/Dasatinib
Description: Three dose levels of daily zileuton will be studied in conjunction with dasatinib to define the MTD
Study: NCT03332940

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tc99m-tilmanocept
Description: Tilmanocept is a radiotracer that accumulates in macrophages by binding to a mannose binding receptor that resides on the surface.
Study: NCT00006265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ara-C
Description: 3 g/sq m IV infusion over 3 hours Days 1-5

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: gemtuzumab ozogamicin
Description: 9 mg/sq m IV infusion over 2 hrs D 1 (Cohort I); D 7 (Cohorts II, IA, \& IV); \& D 14 (Cohort IV) 4.5 mg/sq m IV infusion over 2 hrs D 8 (Cohort I) \& D 14 (Cohort II)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: gemtuzumab ozogamicin
Description: 9 mg/sq m IV infusion over 2 hrs D 1 (Cohort I); D 7 (Cohorts II, IA, \& IV); \& D 14 (Cohort IV) 4.5 mg/sq m IV infusion over 2 hrs D 8 (Cohort I) \& D 14 (Cohort II)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: gemtuzumab ozogamicin
Description: 9 mg/sq m IV infusion over 2 hrs D 1 (Cohort I); D 7 (Cohorts II, IA, \& IV); \& D 14 (Cohort IV) 4.5 mg/sq m IV infusion over 2 hrs D 8 (Cohort I) \& D 14 (Cohort II)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: gemtuzumab ozogamicin
Description: 9 mg/sq m IV infusion over 2 hrs D 1 (Cohort I); D 7 (Cohorts II, IA, \& IV); \& D 14 (Cohort IV) 4.5 mg/sq m IV infusion over 2 hrs D 8 (Cohort I) \& D 14 (Cohort II)
Study: NCT02888158

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Robotic assistance
Description: Robotic assistance will be implemented during Pelvic Trainer training sessions.
Study: NCT02047149

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daily dosing with Zileuton/Dasatinib for CML
Description: Three dose levels of daily zileuton will be studied in conjunction with dasatinib to define the MTD
Study: NCT04426201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CYT107
Description: IM administration at 10µg/kg twice a week for three weeks and up to 7 administrations according to Hospital length of stay

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Same number, volume and frequency of IM administration of saline
Study: NCT01043146

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: COR-1
Description: single intravenous administration of 10, 40, 80, 160 or 240 mg of COR-1

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: intravenous 0.9 % NaCl
Study: NCT03234777

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Whiteboard animation video
Description: Developed via qualitative research with parents of children with acute gastroenteritis.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Regular video
Description: Developed by CDC
Study: NCT03568539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI308
Description: IBI308 200mg IV infusion, every 3 weeks.
Study: NCT04270019

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Standard solution of sterile normal saline.
Study: NCT04547387

Intervention type: DEVICE
Intervention: Trans-carotid access revascularization with MicroNET covered stent implantation
Description: Implantation of the micronet covered self-expanding carotid stent during temporary cerebral flow reversal achieved with direct common carotid artery puncture
Study: NCT05515172

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindfulness-based Intervention
Description: The intervention was designed by a volunteer multidisciplinary team expert in different mind-body medicine techniques (for example, medicine, psychology, thanatology, meditation, health, and wellness coaches, certified Qi Gong, and yoga instructors) and is made up of 3 components main: micropractices, cohesion and support groups, which will be implemented for a period of 12 weeks.
Study: NCT01690026

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Motivation interviewing based brief intervention
Study: NCT03475888

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Medtronic Reveal LINQ™ Insertable Cardiac Monitor (ICM)
Description: Implantation of Medtronic Reveal LINQ™ ICM
Study: NCT02888158

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pelvic Trainer
Description: The standard Pelvic Trainer simulator for surgical training.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic Trainer
Description: The standard Pelvic Trainer simulator for surgical training.
Study: NCT03881631

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Stress Reduction Program
Description: Group-based intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Living Well Program
Description: Group-based intervention
Study: NCT01690026

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Standard Intervention
Study: NCT00101712

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vildagliptin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vildagliptin Placebo
Study: NCT05291026

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mobile phone-based health information
Description: health education and follow-up messaging, randomly assigned to each participant in the intervention arm using a randomization software, delivered once daily, as short message service (sms)
Study: NCT02597868

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine is be given as a sequential treatment in Metastatic breast cancer patients who are got benefit in chemo treatment.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endocrine therapy
Description: endocrine therapy is be given as a sequential treatment in Metastatic breast cancer patients who are got benefit in chemo treatment,the medicine will be confirmed by the patient's past-treatment.
Study: NCT00473473

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Potassium Dichromate (Homeopathy)
Description: twice daily with an interval of 12 hours, for a period of up to 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo homeopathic remedy
Description: identical to treatment without active component
Study: NCT05041946

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo (Sugar Pill)
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo (Sugar Pill)
Description: Given PO
Study: NCT00409864

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic biliary stenting, Percutaneous biliary stenting
Description: percutaneous 10 F stent, endoscopic 10 F stent insertion

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic biliary stenting, Percutaneous biliary stenting
Description: percutaneous 10 F stent, endoscopic 10 F stent insertion
Study: NCT00331214

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone Transdermal System
Description: testosterone patch (300 mcg/day), patch changed twice a week for six months

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: placebo patch
Description: placebo patch replaced every 3-4 days for 6 months
Study: NCT03545789

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]MNI-958
Description: Subjects will undergo PET imaging using \[18F\]MNI-958, a PET radioligand for imaging tau.
Study: NCT01244100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PL2200 fasted
Description: Fasted state
Study: NCT02556827

Intervention type: OTHER
Intervention: Obtaining a blood sample
Description: Total oxidant capacity (TOC), total antioxidant capacity (TAC), oxidative stress index (OSI), paraoxonase-1 (PON-1), aryl esterase (ARES), myeloperoxidase (MPO), tumor necrosis factor-alpha (TNF-α), interleukin-1beta (IL-1β), matrix metalloproteinase-1 (MMP-1) and matrix metalloproteinase-9 (MMP-9) levels in venous blood were measured.

Intervention type: OTHER
Intervention: Obtaining a blood sample
Description: Total oxidant capacity (TOC), total antioxidant capacity (TAC), oxidative stress index (OSI), paraoxonase-1 (PON-1), aryl esterase (ARES), myeloperoxidase (MPO), tumor necrosis factor-alpha (TNF-α), interleukin-1beta (IL-1β), matrix metalloproteinase-1 (MMP-1) and matrix metalloproteinase-9 (MMP-9) levels in venous blood were measured.

Intervention type: DEVICE
Intervention: Reflectance confocal microscopy
Description: 1mm2-sized 10 images were taken from right cheek and forehead; the number of demodex, follicle, the number of mite per follicle, the number of infested follicle and the number of mite per infested follicle were calculated with RCM. And photoaging severity were also assessed by using RCM.

Intervention type: DEVICE
Intervention: Reflectance confocal microscopy
Description: 1mm2-sized 10 images were taken from right cheek and forehead; the number of demodex, follicle, the number of mite per follicle, the number of infested follicle and the number of mite per infested follicle were calculated with RCM. And photoaging severity were also assessed by using RCM.

Intervention type: DEVICE
Intervention: Sebumeter
Description: Sebum rate at forehead and right cheek were evaluated with sebumeter

Intervention type: DEVICE
Intervention: Sebumeter
Description: Sebum rate at forehead and right cheek were evaluated with sebumeter

Intervention type: DEVICE
Intervention: Video dermoscopy
Description: Dermoscopic photoaging scale were assessed by using video dermoscopy.

Intervention type: DEVICE
Intervention: Video dermoscopy
Description: Dermoscopic photoaging scale were assessed by using video dermoscopy.
Study: NCT03347188

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fremanezumab
Description: Fremanezumab will be administered per dose and schedule specified in the arm.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching to fremanezumab will be administered per schedule specified in the arm.
Study: NCT01317381

Intervention type: PROCEDURE
Intervention: Observational
Description: Blood draw
Study: NCT03403374

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: evolocumab
Description: Administered by SC injection via autoinjector (AI)/pen
Study: NCT02219347

Intervention type: DRUG
Group type: OTHER
Intervention: DMARD cessation
Description: Complete cessation of non-biologic DMARD therapy (single or combination of methotrexate, sulphasalazine and/or hydroxychloroquine)
Study: NCT01681017

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: HBB/ENC Training and Equipment
Description: See the detailed description section

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: HBB/ENC Training and Equipment
Description: See the detailed description section

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: HBB/ENC Training and Equipment
Description: See the detailed description section

Intervention type: OTHER
Group type: OTHER
Intervention: HBB/ENC supplies
Description: Staffs associated with participating facilities receive HBB/ENC training and use related equipment.
Study: NCT01244100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PL2200 fed
Description: Fed state
Study: NCT00651677

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: HAL proctectomy
Description: Hand-assisted laparoscopic proctectomy
Study: NCT02330484

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Give incentives to patients based on their own HbA1c improvement
Description: Give incentives to patients based on their own HbA1c improvement

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Give incentives to patients based on their own HbA1c improvement
Description: Give incentives to patients based on their own HbA1c improvement

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Give incentives to physician based on their patient's HbA1c improvement
Description: Give incentives to physician based on their patient's HbA1c improvement

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Give incentives to physician based on their patient's HbA1c improvement
Description: Give incentives to physician based on their patient's HbA1c improvement
Study: NCT00791310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flucis
Description: FDG injected i.v
Study: NCT00651677

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: straight laparoscopic proctectomy
Description: straight laparoscopic proctectomy
Study: NCT04750603

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone furoate (FF)/Vilanterol (VI)
Description: Patients with a positive exercise challenge test were allocated to a single administration of salbutamol (400 µg) and 22 to FF/VI (92/22 µg) in a double blind, double dummy method to assess the short-term effect on exercise induced complaints

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Salbutamol
Description: Patients with a positive exercise challenge test were allocated to a single administration of salbutamol (400 µg) and 22 to FF/VI (92/22 µg) in a double blind, double dummy method to assess the short-term effect on exercise induced complaints.
Study: NCT00651677

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hand-assisted laparoscopic proctectomy
Description: hand-assisted laparoscopic proctectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SL Proctectomy
Description: Straight laparoscopic proctectomy
Study: NCT00586274

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CD34 selected haploidentical PBSCT
Description: Infusion of CD34 selected haploidentical PBSCT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: day -8 through day -4 Fludarabine 30 mg/m\^2

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: T cell infusion
Description: At least 30 days after the stem cell infusion, patients will be dosed with T cells. This study will begin with a dose of T cells known not to cause GvHD even in haploidentical recipients, even when the T cells administered have not first been allodepleted. Dose escalation will follow a traditional up and down method, but as results become available they will be used to determine subsequent dose levels by the continual reassessment method. Initially, 2 patients will be entered beginning at dose level 1. Each and every patient will receive up to three additional injections of T cells at the same dose, at monthly intervals, provided there is no evidence of grade 2 or higher GVHD, until total T cell numbers are \> 1000/ul.~Dose level -1 (1 x 10\^3 T cells/Kg); Dose level 1 (1 x 10\^4 T cells/Kg); Dose level 2 (1 x 10\^5 T cells/Kg); Dose level 3 (1 x 10\^6 T cells/Kg); Dose level 4 (5 x 10\^6 T cells/Kg)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Campath 1h
Description: 10 mg iv over 4 hours day-8 through day-6

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-CD45
Description: anti-CD45 400 ug/kg over 6 hours day -5 through day -2
Study: NCT00438425

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary Portfolio - Intensive
Description: Dietitians advised participants to consume the following therapeutic diet components (\<7% of energy saturated fat, \<200 mg/d cholesterol) plus the combination of viscous fibers, soy protein, plant sterols and nuts. The portfolio diet plan will include foods which contribute 9.8 g/1000 kcal viscous fiber as B-glucan (oats, barley, oat bran breads and soups) and psylliium (cereal), 0.94 g plant sterol/1000 kcal diet (in sterol margarine), 22.5 g soy protein/1000 kcal (soy burgers, dogs, links, other meat analogues, milks, yogurts and cheese) and 22.5 g nuts/1000 kcal as part of a low fat vegetarian diet. Participants received 7 visits during a 6-month period with the study dietitian.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary Portfolio - Routine
Description: Dietitians advised participants to consume the following therapeutic diet components (\<7% of energy saturated fat, \<200 mg/d cholesterol) plus the combination of viscous fibers, soy protein, plant sterols and nuts. The portfolio diet plan will include foods which contribute 9.8 g/1000 kcal viscous fiber as B-glucan (oats, barley, oat bran breads and soups) and psylliium (cereal), 0.94 g plant sterol/1000 kcal diet (in sterol margarine), 22.5 g soy protein/1000 kcal (soy burgers, dogs, links, other meat analogues, milks, yogurts and cheese) and 22.5 g nuts/1000 kcal as part of a low fat vegetarian diet. Participants received 2 visits during a 6-month period with the study dietitian.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Control (low saturated fat therapeutic diet)
Description: Dietitians advised participants to consume the following therapeutic diet components (\<7% of energy saturated fat, \<200 mg/d cholesterol) with a focus on low-fat dairy and whole grain cereals together with fruit and vegetables as part of a low fat vegetarian diet, and avoidance of the specific portfolio components.
Study: NCT02148809

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 1mL of I-131 Human Serum Albumin is injected prior to the measurements
Study: NCT02550054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epo
Description: Epo is administered 1000 U/kg, iv in 48 hours after premature birth, and at 48 hours interval for 3 doses per week. After 6 doses, subcutaneously 400 U/Kg per injection and 3 doses per week until at corrected age of 34 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline is administered 5ml, iv at 3 to 6 hours after premature birth, and at 48 hours interval for 3 doses per week. After 6 doses, Subcutaneously 3 doses per week until at corrected age of 34 weeks.
Study: NCT02127476

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KHK6640
Description: Single ascending dose and multiple ascending doses administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Single ascending dose and multiple ascending doses administration
Study: NCT01793740

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cogmed
Description: Computer based program that aims to improve children's memory, attention, and processing speed.
Study: NCT03453385

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Electronic Cigarette
Description: An e-cigarette and four weeks of e-liquid provided to participants.
Study: NCT03999944

Intervention type: DEVICE
Group type: OTHER
Intervention: positive airway pressure system
Description: Positive Airway Pressure System

Intervention type: DEVICE
Group type: OTHER
Intervention: positive airway pressure system
Description: Positive Airway Pressure System
Study: NCT03033732

Intervention type: DRUG
Group type: OTHER
Intervention: Methadone
Description: Methadone is a synthetic analgesic drug used as a substitute drug in the treatment of opioid use disorder. Methadone is administered via strict daily witnessed ingestion.

Intervention type: DRUG
Group type: OTHER
Intervention: Buprenorphine-Naloxone
Description: Buprenorphine/Naloxone is an opioid agonist treatment used to treat opioid use disorder. Buprenorphine/Naloxone is administered via flexible take home dosing once the patient has reached stabilization as per physician discretion.
Study: NCT02518243

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient's answer with non pharmacological therapeutic
Description: Installation at patient's home of :~* aromatherapy~* music therapy~* cognitive training in multimedia application offering cognitive games
Study: NCT00504920

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Questionnaires (30 minutes each) + instruction on telephone survey system for measuring symptoms. Questionnaires 2 times a week while in the hospital or until able to use the telephone survey system.
Study: NCT01886469

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLD100-B
Description: d-amphetamine sulfate capsules, 30 mg, CII (25% SR, 30% pH coat, slow release; formulation B)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLD100-B
Description: d-amphetamine sulfate capsules, 30 mg, CII (25% SR, 30% pH coat, slow release; formulation B)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLD100-C
Description: d-amphetamine sulfate capsules, 30 mg, CII (20% SR, 20% pH coat, fast release; formulation E) - this intervention may be deemed unnecessary based on results from Intervention 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLD100-C
Description: d-amphetamine sulfate capsules, 30 mg, CII (20% SR, 20% pH coat, fast release; formulation E) - this intervention may be deemed unnecessary based on results from Intervention 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLD100-E
Description: d-amphetamine sulfate capsules, 30 mg, CII (20% SR, 20% pH coat, medium release; formulation E) - this intervention may be deemed unnecessary based on results from Interventions 1 and 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLD100-E
Description: d-amphetamine sulfate capsules, 30 mg, CII (20% SR, 20% pH coat, medium release; formulation E) - this intervention may be deemed unnecessary based on results from Interventions 1 and 2.
Study: NCT03658941

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No dural tenting techniques
Description: Not applying dural tenting sutures during closure of a craniotomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dural tenting techniques
Description: Applying at least 3 dural tenting sutures during closure of a craniotomy
Study: NCT01366196

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin 150 mg
Description: Patients will receive two 75 mg capsules of pregabalin 1 hour before surgery. They continue to take 2 capsules of 75 mg (total 150 mg) until POD 14.